Pre-market most active 09 Apr 2026: 4564.T OncoTherapy Science at JPY 27.00 signals heavy-volume move

In pre-market trading on 09 Apr 2026 the focus keyword 4564.T stock is drawing attention after a JPY 2.00 jump to JPY 27.00, up 8.00% on volume 190,389,800.00. The move makes OncoTherapy Science, Inc. (4564.T) one of the most active names on the JPX this session. The surge follows a cluster of clinical updates and heavy buying that pushed the price above the 50-day average of JPY 21.22. Traders should note the high relative volume of 3.56x and intraday range JPY 25.00–28.00, which points to short-term volatility and possible follow-through into the Tokyo session.

Pre-market price and volume snapshot for 4564.T stock

OncoTherapy Science (4564.T) opened at JPY 27.00.00 versus a previous close of JPY 25.00.00, trading between JPY 25.00.00 and JPY 28.00.00 in pre-market. Volume is 190,389,800.00 against an average volume of 51,509,764.00, a 3.56x surge that makes the name one of Japan’s most active pre-market issues. The intraday volatility is confirmed by an ATR of 1.69 and a daily performance gain of 8.00%.

Fundamentals and valuation: 4564.T analysis

Fundamentally OncoTherapy carries a market cap of JPY 9,278,377,173.00 with EPS -2.83 and a negative PE at -9.54. Price-to-sales stands at 11.83 and price-to-book at 4.55, reflecting premium expectations despite losses. Cash per share is JPY 6.06 and book value per share is JPY 5.93, supporting a strong current ratio of 8.51. Research intensity is high, with R&D to revenue near 65.79%, consistent with a biotech in clinical stages. These metrics position the company far from sector averages for profitable healthcare names, and they frame headline moves as speculation around pipeline value rather than earnings strength.

Pipeline catalysts and risks shaping 4564.T stock moves

OncoTherapy’s clinical pipeline drives market interest. Key assets include OTS167 and OTS964 small molecules and peptide vaccines such as S-588410 (Phase III for esophageal cancer). Upcoming events include the next earnings announcement on 2026-05-11 and potential trial readouts that can act as catalysts. Positive trial news would justify sharp re-rating; negative or delayed data risks steep sell-offs.

Biotech-specific risks are dilution from equity raises, regulatory hurdles, and binary clinical outcomes. Given heavy pre-market volume, the stock is reacting more to headline risk and positioning than to near-term revenue improvements.

Technical read and trading levels for 4564.T stock

Technically the name shows momentum: price is above the 50-day average (JPY 21.22) and 200-day average (JPY 23.90). RSI at 76.36 and MFI 85.59 read as overbought, while MACD histogram is positive (0.46), indicating bullish but stretched momentum. Bollinger upper band sits at JPY 25.50, so current price near JPY 27.00 is above the short-term band and signals intraday caution.

Key levels: near-term resistance at the year high JPY 35.00, support at prior lows JPY 19.00 and the 200-day average JPY 23.90. A conservative short-term price target for momentum traders is JPY 31.00, while a defensive stop beneath JPY 23.00 limits downside exposure.

Meyka AI grade and 4564.T stock forecast

Meyka AI rates 4564.T with a score of 66.01 out of 100 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a yearly price of JPY 17.31, a monthly price of JPY 16.61, and a three-year level near JPY 12.52. Compared with the current JPY 27.00, the model implies a near-term downside of -35.85% to the yearly projection and -38.48% to the monthly projection. Forecasts are model-based projections and not guarantees.

Trading takeaways and strategy for most active session

As a most-active pre-market pick, 4564.T stock suits event-driven traders who can accept high volatility and quick exits. Volume gives intraday liquidity, but technical indicators warn of overbought conditions. For traders: size positions small, use disciplined stops near JPY 23.00, and watch newsflow around clinical updates and the 2026-05-11 earnings date.

Longer-term investors should weigh pipeline potential against a costly valuation and negative EPS. Liquidity is high today, but fundamental catalysts remain binary.

Final Thoughts

4564.T stock is one of the JPX most-active pre-market names on 09 Apr 2026 after a JPY 2.00 rise to JPY 27.00 and volume of 190,389,800.00. Short-term trading looks attractive for momentum players because of strong volume and positive technical momentum, but indicators show overbought readings and elevated risk. Fundamentally the company remains loss-making with EPS -2.83 and a negative PE; valuation metrics such as P/S 11.83 and P/B 4.55 reflect premium pricing for clinical-stage assets. Meyka AI rates 4564.T at 66.01/100 (Grade B, HOLD) and its forecast model projects a yearly level of JPY 17.31, implying an estimated downside of -35.85% against the current price. Traders should monitor clinical readouts and the 2026-05-11 earnings announcement; use tight risk controls and expect headline-driven swings. Forecasts are projections, not guarantees, and any position should align with a clear stop-loss and event timeline.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.